159 related articles for article (PubMed ID: 38233781)
1. Longitudinal analysis of quality of life in primary lung cancer patients with chlamydia pneumoniae infection: a time-to-deterioration model.
Chen Z; Zhuang J; Liu M; Xu X; Liu Y; Yang S; Xie J; Lin N; Lai F; He F
BMC Pulm Med; 2024 Jan; 24(1):36. PubMed ID: 38233781
[TBL] [Abstract][Full Text] [Related]
2. Association between physical activity and health-related quality of life: time to deterioration model analysis in lung adenocarcinoma.
Zhuang J; Liu Y; Xu X; Cai Y; Liu M; Chen Z; Yang S; Lin J; Hu Z; Kang M; Lin M; He F
J Cancer Surviv; 2023 Dec; 17(6):1769-1779. PubMed ID: 36192668
[TBL] [Abstract][Full Text] [Related]
3. Establishing Meaningful Change Thresholds in Patient-Reported Outcomes Among Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in ALTA-1L Trial.
Beaumont JL; Lin HM; Goodman E; Yu H; Geiger A; Hudgens S
Value Health; 2024 Feb; 27(2):182-189. PubMed ID: 37951539
[TBL] [Abstract][Full Text] [Related]
4. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life.
Bergman B; Aaronson NK; Ahmedzai S; Kaasa S; Sullivan M
Eur J Cancer; 1994; 30A(5):635-42. PubMed ID: 8080679
[TBL] [Abstract][Full Text] [Related]
5. Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3.
Makharadze T; Quek RGW; Melkadze T; Gogishvili M; Ivanescu C; Giorgadze D; Dvorkin M; Penkov K; Laktionov K; Nemsadze G; Nechaeva M; Rozhkova I; Kalinka E; Gessner C; Moreno-Jaime B; Passalacqua R; Konidaris G; Rietschel P; Gullo G
Cancer; 2023 Jul; 129(14):2256-2265. PubMed ID: 37151113
[TBL] [Abstract][Full Text] [Related]
6. Quality of life of lung cancer patients: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13.
Chie WC; Yang CH; Hsu C; Yang PC
Qual Life Res; 2004 Feb; 13(1):257-62. PubMed ID: 15058806
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L).
Garcia Campelo MR; Lin HM; Zhu Y; Pérol M; Jahanzeb M; Popat S; Zhang P; Camidge DR
Lung Cancer; 2021 May; 155():68-77. PubMed ID: 33744781
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
9. Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses.
Lenz HJ; Argiles G; Yoshino T; Lonardi S; Falcone A; Limón ML; Sobrero A; Hastedt C; Peil B; Voss F; Griebsch I; Van Cutsem E
Clin Colorectal Cancer; 2019 Dec; 18(4):269-279.e5. PubMed ID: 31628043
[TBL] [Abstract][Full Text] [Related]
10. Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study.
Brusniak K; Feisst M; Sebesteny L; Hartkopf A; Graf J; Engler T; Schneeweiss A; Wallwiener M; Deutsch TM
JMIR Cancer; 2021 Oct; 7(4):e25776. PubMed ID: 34636732
[TBL] [Abstract][Full Text] [Related]
11. Combined and interaction effect of chlamydia pneumoniae infection and smoking on lung cancer: a case-control study in Southeast China.
Xu X; Liu Z; Xiong W; Qiu M; Kang S; Xu Q; Cai L; He F
BMC Cancer; 2020 Sep; 20(1):903. PubMed ID: 32962687
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular health-related quality of life in cancer: a prospective study comparing the ESC HeartQoL and EORTC QLQ-C30 questionnaire.
Anker MS; Potthoff SK; Lena A; Porthun J; Hadzibegovic S; Evertz R; Denecke C; Fröhlich AK; Sonntag F; Regitz-Zagrosek V; Rosen SD; Lyon AR; Lüscher TF; Spertus JA; Anker SD; Karakas M; Bullinger L; Keller U; Landmesser U; Butler J; von Haehling S
Eur J Heart Fail; 2023 Sep; 25(9):1635-1647. PubMed ID: 37369985
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in patients with lung cancer: validation of the Mexican-Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire.
Arrieta Ó; Núñez-Valencia C; Reynoso-Erazo L; Alvarado S; Flores-Estrada D; Angulo LP; Oñate-Ocaña LF
Lung Cancer; 2012 Jul; 77(1):205-11. PubMed ID: 22387006
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal health-related quality of life analysis in oncology with time to event approaches, the STATA command qlqc30_TTD.
Bascoul-Mollevi C; Savina M; Anota A; Barbieri A; Azria D; Bonnetain F; Gourgou S
Comput Methods Programs Biomed; 2018 May; 158():153-159. PubMed ID: 29544781
[TBL] [Abstract][Full Text] [Related]
15. Quality of life measures (EORTC QLQ-C30 and SF-36) as predictors of survival in palliative colorectal and lung cancer patients.
Grande GE; Farquhar MC; Barclay SI; Todd CJ
Palliat Support Care; 2009 Sep; 7(3):289-97. PubMed ID: 19788770
[TBL] [Abstract][Full Text] [Related]
16. Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.
Barlesi F; Garon EB; Kim DW; Felip E; Han JY; Kim JH; Ahn MJ; Fidler MJ; Gubens MA; de Castro G; Surmont V; Li Q; Deitz AC; Lubiniecki GM; Herbst RS
J Thorac Oncol; 2019 May; 14(5):793-801. PubMed ID: 30711649
[TBL] [Abstract][Full Text] [Related]
17. Does it matter how we evaluate HRQOL? Longitudinal comparison of the EORTC QLQ-C30/QLQ-OG25 and FACT-E.
Darling GE; Sulman J; Espin-Garcia O; Trudel JG; Atenafu EG; Kidane B
J Cancer Surviv; 2021 Aug; 15(4):641-650. PubMed ID: 33106994
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
Garon EB; Cho BC; Luft A; Alatorre-Alexander J; Geater SL; Kim SW; Ursol G; Hussein M; Lim FL; Yang CT; Araujo LH; Saito H; Reinmuth N; Medic N; Mann H; Shi X; Peters S; Mok T; Johnson M
Lung Cancer; 2023 Dec; 186():107422. PubMed ID: 37992595
[TBL] [Abstract][Full Text] [Related]
19. International validation of two EORTC questionnaires for assessment of health-related quality of life for patients with high-grade non-Hodgkin lymphoma (QLQ-NHL-HG29) and low-grade non-Hodgkin lymphoma (QLQ-NHL-LG20).
Oerlemans S; Efficace F; Kyriakou C; Freitas AC; Shamieh O; Creutzberg CL; Lehmann J; Petranovic D; Nagele E; Bredart A; Dong D; Scholz CW; Caocci G; Molica S; Griskevicius L; Xochelli A; Kieffer JM; Agelink van Rentergem JA; Alrjoub W; Mueller A; Gomes Da Silva M; Alves da Costa F; Malak S; Cocks K; van de Poll-Franse LV;
Cancer; 2023 Sep; 129(17):2727-2740. PubMed ID: 37204189
[TBL] [Abstract][Full Text] [Related]
20. Association between the Preoperative Dietary Antioxidant Index and Postoperative Quality of Life in Patients with Esophageal Squamous Cell Carcinoma: A Prospective Study Based on the TTD Model.
Zhang J; Zhou J; Huang Y; Lin Z; Zhang S; Qiu M; Xiang Z; Hu Z
Nutrients; 2023 Jun; 15(13):. PubMed ID: 37447155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
